American Oncology Network Stock Price, News & Analysis

American Oncology Network (NASDAQ:AONC) has announced that Auerbach Hematology and Oncology Associates PC in Baltimore has joined its network and will be rebranded as The Center for Cancer and Blood Disorders (CCBD)—Baltimore. The practice, led by renowned experts Dr. Michael Auerbach and Dr. Huzefa Bahrain, along with CRNP Stephanie Horrocks, brings 24 years of experience in hematology and oncology care.

The partnership will enable the practice to expand patient services, increase clinical trial offerings, and explore new market opportunities while maintaining their commitment to high-quality, community-based care. CCBD-Baltimore will serve patients across Baltimore, Bethesda, and Germantown, Maryland, offering comprehensive cancer care services including diagnostics, treatment, clinical trials, and survivorship programs.

Florida Oncology and Hematology, a partner practice of American Oncology Network (NYSE:AONC), has expanded its Fort Myers clinic with the addition of radiology services. The enhanced facility now features PET services, 12 exam rooms, nearly 30 infusion chairs, and an on-site lab.

The practice, led by medical oncologists Dr. Van den Bergh, Dr. Parsa, and Dr. Mann, operates five clinics across Florida. The expansion includes advanced diagnostic capabilities and Radioligand Therapy for treating various cancers. The facility aims to provide comprehensive cancer care services in a single location for Lee County residents.

Hope Cancer Care of Nevada, in partnership with American Oncology Network (NYSE:AONC), has expanded its presence in Nevada with the opening of a new clinic in Henderson, marking its third location in the state. The new facility, located at 3035 W. Horizon Ridge Parkway, is led by board-certified medical oncologist Dr. Raja S. Mehdi.

The clinic features private exam rooms, an infusion room, and a specialty pharmacy for oral oncolytics. This expansion aims to provide Clark County residents with improved access to comprehensive oncology and hematology services, offering services including diagnosis, treatment, survivorship, and patient support close to home.

Florida Oncology and Hematology, a partner practice of American Oncology Network (AON), has relocated its Health Parkway clinic in Naples to a larger facility at 15455 Collier Blvd., Suite 101 in the Lintree Medical Plaza. The expanded clinic features enhanced services including PET services, an infusion room, additional private exam rooms, in-house lab and pathology services, and an onsite specialty pharmacy for oral oncolytics.

Board-certified medical oncologist Dr. Ferdy Santiago and Board-certified hematologist Dr. Deborah Glick are now seeing patients at the new location. The practice also recently expanded its other Naples-area clinic at Goodlette-Frank Road in June. Florida Oncology and Hematology operates five clinic locations serving patients in Cape Coral, Clearwater, Fort Myers, Naples, and surrounding areas.

Florida Oncology and Hematology, a partner of American Oncology Network (AONC), has relocated its Naples-Goodlette clinic to a larger facility at 708 Goodlette-Frank Road. The expanded location features additional private exam rooms, an infusion room, in-house lab and pathology services, and an onsite specialty pharmacy for oral oncolytics. Board-certified medical oncologists Dr. Zanetta Lamar, Dr. Ferdy Santiago, and hematologist Dr. Deborah Glick are accepting patients at the new location. The practice, which serves patients across Cape Coral, Clearwater, Fort Myers, Naples, and surrounding areas, aims to provide enhanced cancer care through personalized treatment plans in a community-based setting. The relocation enables the practice to expand patient services, add staff for one-on-one care, and maintain their commitment to affordable, high-quality oncology treatment.

American Oncology Network (AONC) showcased multiple research studies at the ASCO 2025 Annual Meeting in Chicago from May 30-June 3. AON physicians and leaders presented research across various oncology fields, including clinical trials, real-world data analysis, and cost-effectiveness studies. Key presentations covered topics such as neuroendocrine neoplasms, breast cancer treatments, racial representation in clinical trials, pharmacovigilance studies, and cost-effective cancer care through biosimilars. Notable research included studies on ABBV-706 for neuroendocrine neoplasms, Bria-IMT trials in metastatic breast cancer, and multiple real-world analyses of cancer treatments. AON currently offers access to over 150 clinical trials through its network of community oncology practices.

American Oncology Network (AONC) announced the expansion of radioligand therapy (RLT) access across its network, with six community oncology practices now offering these advanced cancer treatments. The network has already administered over 300 treatments to nearly 70 patients across five partner practices.

The practices offer three FDA-approved radiopharmaceuticals: Pluvicto™ for metastatic castration-resistant prostate cancer, Lutathera® for gastroenteropancreatic neuroendocrine tumors, and Xofigo® for symptomatic mCRPC with bone metastases. RLT works by delivering targeted radiation directly to cancer cells while minimizing damage to healthy tissue.

American Oncology Network (AONC) has appointed Joe Verschleiser as Chief Growth and Performance Officer. In his new role, Verschleiser will lead growth strategy and performance optimization for AON partner practices, focusing on expansion and new business line opportunities. He brings over a decade of healthcare experience, including executive leadership roles at Unified Women's Healthcare, where he served as president of the West Division overseeing operations for more than 200 physicians. His previous experience includes positions in financial strategy, mergers and acquisitions, and investment banking at firms like Jefferies and Rothschild & Co.

Dr. Sakeer Hussain, a medical oncologist at Heartland Oncology and Hematology, has been named a 2025 Advocacy Champion by the Association for Clinical Oncology (ASCO). The recognition was announced during ASCO's annual Advocacy Summit in Washington, D.C. Dr. Hussain was honored for his significant contributions to cancer policy advancement, including meetings with congressional leaders, testifying before the Iowa House of Representatives, and hosting his local congressman to showcase community oncology care.

His advocacy work has focused on critical issues such as drug shortages, research funding, telehealth access, prior authorization reform, and opposing non-medical switching. Dr. Hussain's efforts align with ASCO's mission to support high-quality, equitable cancer care, regardless of patients' geography, income, or background.